Companies that feel they are under a “constant state of inspection” may be able to ease the burden by helping regulators understand who has already inspected their pharmacovigilance systems and when.
Companies that feel they are under a “constant state of inspection” may be able to ease the burden by helping regulators understand who has already inspected their pharmacovigilance systems and when.